Accolade (ACCD) Stock Price
Accolade Price
Over the last 6 years Accolade grew revenue by 33.2% annually, reaching 408.34 M USD. For Accolade, the net margin of -24.4% is up versus -39.6% a few years ago. The consensus 12-month price target for Accolade is 7.17 USD, about 2.1% above where the stock trades today. Of 18 analysts, 7 rate the stock a buy — an overall Hold consensus.
Accolade stock price
Accolade business model & stock analysis
Frequently asked questions about Accolade
Accolade Inc operates as a healthcare technology and services company. The company's business model is based on providing personalized health and benefits solutions to individuals and their families. Accolade's services include healthcare navigation, behavioral health support, benefits advisory, and chronic condition management. By combining technology and human touch, Accolade aims to simplify and improve access to healthcare for its clients. Through their platform, Accolade Inc aims to empower individuals in making informed healthcare decisions, managing their health conditions, and optimizing their overall well-being. Accolade Inc strives to enhance healthcare outcomes and reduce costs for both individuals and employers.
Accolade Inc is primarily active in the healthcare and technology industries.
Accolade Inc faces competition from various companies in the market. Some of its main competitors include Teladoc Health, Livongo Health, and Health Catalyst. These companies also operate in the healthcare technology sector, providing similar services and solutions. However, Accolade Inc distinguishes itself through its unique combination of personal health support and advanced technology platforms, offering a comprehensive approach to healthcare management and improving patient outcomes.
Accolade Inc, founded in 2007, is a leading technology-enabled healthcare company headquartered in Seattle, Washington. The company provides personalized healthcare and benefits solutions to its clients, including employers, health plans, and health systems. With a mission to improve the healthcare experience for individuals and their families, Accolade Inc combines cutting-edge technology and human expertise to deliver personalized health and benefits services. Over the years, Accolade Inc has established itself as a trusted partner in the industry, leveraging their deep domain knowledge and innovative solutions to support individuals in navigating the complex healthcare landscape efficiently and effectively. This commitment to customer-centric healthcare has propelled Accolade Inc to become a recognized leader in the industry.
Accolade Inc has achieved several significant milestones since its inception. The company successfully completed its initial public offering (IPO) in July 2020, marking a major achievement in its growth trajectory. In recent years, Accolade Inc has formed strategic partnerships with various renowned healthcare organizations, enhancing its market presence and enabling provision of personalized healthcare solutions. With its innovative technology and dedicated team, Accolade Inc has rapidly expanded its customer base, serving millions of individuals across the United States. The company's revolutionary approach to healthcare management has garnered recognition, including being named a Fast Company's Most Innovative Company in 2021. Accolade Inc continues to drive innovation in the healthcare industry, revolutionizing the way individuals access and navigate their healthcare choices.
Accolade Inc is primarily present in the United States of America.
Accolade Inc represents values of innovation, collaboration, and customer-centricity. With a strong corporate philosophy focused on improving healthcare experiences, Accolade Inc strives to empower individuals and families to navigate their health and benefits in a personalized and effective manner. By combining technology and human expertise, the company aims to deliver comprehensive support, enhance outcomes, and reduce healthcare costs. Accolade Inc's commitment to delivering exceptional service and its emphasis on providing personalized health advocacy aligns with its mission to empower individuals and transform the healthcare industry.
Analysts currently set an average price target of 6.83 USD for the Accolade stock (median: 7.17 USD), implying -2.7 % versus the latest price. The consensus is based on 18 analyst ratings.
16 analysts currently rate the Accolade stock: 0 recommend buying, 13 holding and 3 selling. For 2026, analysts expect Accolade to generate revenue of 521.26 M USD and earnings per share of -1.01 USD.
Converted at the current exchange rate, the Accolade share trades at 6.24 EUR (7.02 USD).
The Accolade share (ACCD) is listed on 4 stock exchanges, including: NASDAQ (ACCD), Frankfurt (4NE1.F), München (4NE1.MU), Düsseldorf (4NE1.DU).
Accolade is a technology and healthcare company that develops innovative solutions for improving healthcare.
The expected revenue of Accolade is 521.26 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Accolade is -81.17 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Accolade is currently -6.97. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Accolade stock.
The price-to-sales ratio (P/S) of Accolade is currently 1.09. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Accolade stock.
The Eulerpool Quality Score for Accolade is 2/10.
The ISIN of Accolade is US00437E1029. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Accolade is A2P7Z2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Accolade is ACCD. The ticker symbol is used to trade Accolade shares on the stock exchange.
Accolade stock
Accolade Peer Group
Accolade Ticker
Accolade FIGI
All fundamentals and in-depth analysis of Accolade
Our stock analysis for Accolade stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Accolade. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.